President & CEO of Robles BioCeutics | Developers of Advanced Senolytic & Regenerative Cosmeceuticals
San Diego, California
Joined September 2024
- Tweets6.6K
- Following412
- Followers2.4K
- Likes3.5K
Pinned Tweet
My presentation at the American Association for Immunology.
youtube.com/watch?v=VBjboNxz…
Major finding ! Skin nerves prevent acceleration of skin aging....specifically, skin-innervating glutamatergic neurons ....glutamate prevents aging?
linkinghub.elsevier.com/retr…
One question helped inspire the patent behind Robles BioCeutics: what if stem cells become most regenerative when they think the body is injured?
Join me today at 12:00 PM PST as I share the science, research, and vision behind our approach to regenerative dermatology.
🎥 youtu.be/VBjboNxz9dk
Maria Robles retweeted
I hope you feel much better every day. I work for Dr. Patrick at hie ES bldgs. Going to clinic this morning to take care of the cells.
I love scientific wins…Doubling of survival time in patients with #pancreatic #cancer !
Using oral ras
inhibitor
When this was presented at #asco there was a standing ovation !
nejm.org/doi/10.1056/NEJMoa2…
Maria Robles retweeted
Out now on @PLOSPathogens ! We discovered that a mouse #herpesvirus #CMV encodes a novel #cellcycle regulating protein within its highly conserved polymerase gene! journals.plos.org/plospathog…
Maria Robles retweeted
Same target, three carrier-isotope platforms, three toxicity profiles.
🔬 ²²⁵Ac-PSMA-617 (small molecule · alpha): Salivary uptake yes.
🔬 ²²⁵Ac-rosopatamab (antibody · alpha): Minimal salivary/renal uptake. Thrombocytopenia replaces xerostomia
🔬 ¹⁷⁷Lu-rosopatamab (antibody · beta): Minimal salivary/renal uptake. Thrombocytopenia replaces xerostomia
The antibody carrier trades salivary toxicity for bone marrow toxicity.
💡 RLT selection is becoming a carrier-and-isotope decision. Organ function, prior therapy, and toxicity tolerance will be a factor
#ProstateCancer #mCRPC #PSMA #Theranostics #RLT #GUOnc #ASCO26
Maria Robles retweeted
As I scan the literature, I continue to be amazed of how far back the realization that the immune system matters regardless of the tumor type and that with loss of T and NK cells, survival is so significantly reduced. Here is a paper since 2012 that states,
"These patients could be proposed for specific treatment approaches, including innovative strategies for immune restoration."
Just imagine if such an approach was available.
sciencedirect.com/science/ar…
Maria Robles retweeted
One of the most humble oncologists on this planet- Dr. Muro from Aichi Cancer Center in Japan.
大好きな室先生。
Maria Robles retweeted
We @OncologyBGLab had an amazing @asco annual meeting #ASCO26 . So much so that we had to make a separate newsletter to cover everything we did. 😊
oncologybg.com/2026/06/03/bg…
Maria Robles retweeted
🎤📚 Wrapped up this academic year’s @univmiami Grand Rounds with an update on some of the major advances in oncology from 2025-2026.
🧬 The presentation focused on precision medicine, the expanding role of #NGS and #liquidbiopsy, novel therapeutics including bispecifics/#BiTEs and #ADCs, key updates from #ASCO26 (including KRAS-targeted therapies and #daraxonrasib), and the growing importance of #Phase1 clinical trials in advancing cancer care.
🔬 I also highlighted advances in NGS and liquid biopsy research at @SylvesterCancer , including our work on tumor evolution and biomarker-driven treatment decisions, as well as resident-led projects evaluating real-world outcomes with tarlatamab.
🙏 Thank you to Dr Weiss and @GlopesMd for the invitation and to everyone who joined the discussion.
#Oncology #PrecisionMedicine #LiquidBiopsy #NGS #Phase1 #CancerResearch @HemOncMiami @oncodaily @umiamimedicine – at Miami, FL
Maria Robles retweeted
Alright. It’s Sunday @ASCO
Everyone awake and alert?
The trial I most wanted to see -
NHS-Galleri at #ASCO26 (Swanton, LBA100): the first randomized trial of an MCED test in 142,000+ NHS participants.
Honest read: the primary endpoint was missed, but thets not the whole story.
The secondary signals make this neither the breakthrough nor the failure the headlines suggest. 🧵
#ASCO26 @OncoAlert @OncBrothers @StephenVLiu @Jani_Chinmay @asco @myESMO @glopesmd @SylvesterCancer @latinamd @iaslc @COlazagasti @openevidence @openmedicinehq @narjustflorezmd @lungoncdoc @drshieldsmd @jackwestmd @n8pennell @mtmdphd @drarturoai @larvol @onclive @rmanochakian @devikadasmd @dryukselurun @dan_morgen @ptarantinomd
@DrJNaidoo @NaglaAKarimMD @Lung_Cancers @DrSanjayPopat @tnewsomdavis @Tony_Calles @ns_chd @BalazsHalmosMD @dr_yakupergun @ipreeshagul @FordePatrick @OncNewsCentral @imedverse @acmoorephd @DipeshUpretyMD @Alfdoc2 @g_mountzios @dmavicente @drshieldsmd @DrRiyazShah
Congratulations to @GlopesMd SAB member of @ImmortaBio for #longevity quote in washington post!!
Truly #senovax is the future of #aging reversal
washingtonpost.com/health/20…
Maria Robles retweeted
A holy grail for our lab has been tracking myeloid cells in human tumors in the same way that we track T and B cells with TCR/BCR.
@vincentzliu and @CalebLareau solved it!
We developed Mitotrek using scATAC-seq + mitochondrial DNA to do exactly this. Using Mitotrek, we find that new myeloid cells clones constantly infiltrate the tumor via circulating monocytes — and that their macrophage or dendritic cell fate is epigenetically programmed before tumor entry.
@10xGenomics @parkerici @CancerResearch @TheMarkFdn
cell.com/cancer-cell/fulltex…
Stem cell exosomes treat hypertrophic scar by suppressing Schwann cells
iubmb.onlinelibrary.wiley.co…
Maria Robles retweeted
Point-of-care AI that cites the guideline, and quick access to the literature. Useful in a busy clinic.
🏥 ASCO guidelines + flowcharts now embedded in @openevidence
📋 Peer-reviewed evidence + direct ASCO source link alongside each response
Practice prompt: "Which patients with prostate cancer should have germline and somatic genomic testing per ASCO guidelines?"
💡Delivers NCCN and ASCO guideline recommendations with ease of use for your quick clinical question
@ASCO #ASCO26 #AIinMedicine
Every oncologist remembers the first @ASCO Guideline they read in fellowship: the systematic review, the evidence tables, the panel consensus behind every recommendation.
Today, OpenEvidence announced an integration of ASCO Guidelines, figures, and flowcharts into the OpenEvidence model. The ASCO Guidelines appear within context, accompanied by peer-reviewed evidence, precise citations, and a direct link to the ASCO website.
Maria Robles retweeted
40% PSA50 in patients who had already received Lu-PSMA with Ac-225 . CONVERGE-01 at #ASCO26.
CONV01-α is Ac-225 conjugated to rosopatamab, a PSMA monoclonal antibody, not a small molecule. All 22 patients Lu-PSMA-exposed; 21/22 taxane-treated.
🎯 PSA50: 40% overall
🔬 Responses in patients primarily refractory to Lu-PSMA
⚠️ No DLTs at RP2D; dry mouth Gr 1-2
Why this matters for your practice: xerostomia is the concern across Act225 future RLT and will be important in clinical practice alongside efficacy 🩺
#mCRPC #ProstateCancer #GUOnc #ASCO26
Maria Robles retweeted
AcTION: first prospective Phase 1 of ²²⁵Ac-PSMA-617 in mCRPC, n=101. RP2D 10 MBq Q8W x6 cycles.
🎯 Chemo/ARPI-naive: PSA50 85.2%
🎯 Post chemo + ARPI, no prior Lu-PSMA: PSA50 58.8%
🎯 Post ¹⁷⁷Lu-PSMA: PSA50 52.5%
🔍 No DLTs, MTD not reached up to 10 MBq
🔍 No G4/5 TRAEs. Dry mouth G1/2 in >90%, mostly unresolved at data cut.
AcTFirst and PSMAcTION are now recruiting
#ProstateCancer #mCRPC #GUOnc #ASCO26
Maria Robles retweeted
The gut microbiome as an IO treatment modifier in mRCC. CBM588 (Clostridium butyricum live biotherapeutic) added to first-line nivo/ipi or nivo/cabo in a combined phase 1 cohort, n=59.
📈 ORR 66.7% vs 20.0% (p=0.001); median PFS 32.1 vs 3.7 months, HR 0.36, p=0.001
🎯 SIG1+ (dysbiosis): PFS 24.9 vs 2.8 months, HR 0.19, p<0.001
🔬 SIG2+ (non-dysbiosis): HR 0.49, p=0.149; no significant benefit
Why this matters for your practice: 💡 Phase 1, n=59, heterogeneous SOC arms. Love the translational and biomarker studies TOPOSCORE as a predictive dysbiosis. S-score association held only with nivo/ipi, not nivo/cabo.
BIOFRONT phase 3 (NCT07383441) will test. @PBarataMD @drulkav
Great presentation by @RWinayak and mentorship by @montypal @NazliDizman
#KidneyCancer #RCC #GUOnc #ASCO26
